Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol

SAN FRANCISCO , Jan. 14, 2020 /PRNewswire/ –  Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration’s ( FDA’s ) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee

Original Source